Danish biotech company Synact Pharma did not get the results the company expected with its main asset AP1189 in a phase 1 study. The company is now trying again with a different delivery method, which will delay the drug's development up to a year.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.